Table 4 Stratification analysis of IL-8 -251 T/A polymorphism in glioma
From: Association between interleukin 8–251 T/A and +781 C/T polymorphisms and glioma risk
Cases | TT | TA | AA | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
n (%) | OR (95 %CI) | P | n (%) | OR (95 %CI) | P | n (%) | OR (95 %CI) | P | ||
Histology | 300 | 96 (32.0) | 1 (Reference) | 120 (40.0) | 1 (Reference) | 84 (28.0) | 1 (Reference) | |||
Astrocytomas | 223 | 73 (33.6) | 1.02 (0.72,1.45) | 0.90 | 88 (39.5) | 0.99 (0.71,1.37) | 0.94 | 62 (27.8) | 0.99 (0.69,1.44) | 0.97 |
Ependymomas | 43 | 12 (27.9) | 0.87 (0.44,1.72) | 0.69 | 18 (41.9) | 1.05 (0.58,1.89) | 0.88 | 13 (30.2) | 1.08 (0.56,2.10) | 0.82 |
Oligodendrogliomas | 19 | 6 (31.6) | 0.99 (0.38,2.54) | 0.98 | 8 (42.1) | 1.05 (0.45,2.47) | 0.91 | 5 (26.3) | 0.94 (0.34,2.59) | 0.91 |
Mixed gliomas | 15 | 5 (33.3) | 1.04 (0.37,2.94) | 0.94 | 6 (40.0) | 1.00 (0.38,2.64) | 1.00 | 4 (26.7) | 0.95 (0.31,2.95) | 0.93 |
WHO Grade | 300 | 96 (32.0) | 1 (Reference) | 120 (40.0) | 1(Reference) | 84 (28.0) | 1 (Reference) | |||
I | 17 | 6 (35.3) | 1.10 (0.42,2.88) | 0.84 | 7 (41.2) | 1.03 (0.42,2.55) | 0.95 | 4 (23.5) | 0.84 (0.28,2.57) | 0.76 |
II | 106 | 34 (32.1) | 1.00 (0.64,1.57) | 0.99 | 51 (48.1) | 1.20 (0.81,1.79) | 0.36 | 21 (19.8) | 0.71 (0.42,1.20) | 0.20 |
III | 76 | 28 (36.8) | 1.15 (0.71,1.88) | 0.57 | 33 (43.4) | 1.09 (0.69,1.72) | 0.73 | 15 (19.7) | 0.71 (0.39,1.29) | 0.26 |
IV | 101 | 28 (27.7) | 0.87 (0.54,1.40) | 0.56 | 29 (28.7) | 0.72 (0.45,1.14) | 0.16 | 44 (43.6) | 1.56 (1.01,2.39) | 0.04 |